-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=57c36bcd-f159-4e7f-b37c-ddebdb49f45d&Preview=1 -
Date
12/23/2011 -
Company Name
Proacta -
Mailing Address
4275 Executive Square La Jolla, CA 92037 -
Company Description
Proacta is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors.Proacta’s first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radiotherapy. PR-104 is in Phase I clinical trials and planned to begin in a second Ph I study and a Ph II study for 2006. The second compound is planned to enter the clinic in 2007.
-
Website
http://www.proacta.com -
Transaction Type
Debt -
Transaction Amount
$500,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. Debt was issued in the form of convertible promissory notes. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed